Lung adenocarcinoma advanced targeted drugs mainly include EGFR mutation, ALK mutation, anti-angiogenesis and other targeted drugs.
Lung adenocarcinoma is a relatively common malignant tumor in clinic, and related targeted drugs have better progress in this disease, and there are different types of targeted drugs applied in this disease, so according to the different conditions of patients, different genetic tests should be done, and the corresponding targeted drugs should be selected to achieve good therapeutic effect.
EGFR is a more mature targeted drug, such as gefitinib, erlotinib, etc. Currently, there are three generations of targeted drugs, and some patients are able to obtain a longer survival period.
Targeted drugs with ALK mutations, such as crizotinib, alectinib, etc., are able to prolong survival in some patients, but the number of people who develop this gene mutation is small.
Anti-angiogenesis targeted drugs, such as bevacizumab.
Therefore, there are different kinds of targeted drugs for lung adenocarcinoma, and the best therapeutic effect can only be achieved by choosing the appropriate drugs according to the corresponding genetic test results of the patients.